A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy.
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2013
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- 17 Jan 2009 New trial record.